B cell growth-promoting activities have recently been described by a number of investigators in both mouse and human models. These activities have been identified in mitogen-induced culture supernatants of normal cells (1, 2), cell lines (3-5), and hybridomas (6-13). These B cell growth factor (BCGF) ~ activities have been detected and measured in a number of different assays. These include the measurement of the proliferation of normal B cells after costimulation with anti-Ig (6, 7, 12, 13) or mitogens (2, 9, 10, 12, 14) , or direct stimulation of B cells from B cell lymphomas (1-3, 11). Since the assay systems and the sources of the lymphokine activities have varied between individual investigators, it has not been possible to conclude whether one or more different factors were responsible for B cell proliferation. Some of us recently described (3) a growth factor from the Dennert line C.C3.11.75, termed (DL)BCGF, 2 which maintained the growth of the in vivo BCL~ tumor line and appeared to bind to receptors on the tumor cells (3). In our early attempts to characterize this material, it was clear that it was unusually * Supported by grants AI-08795 and CA-09174 from the National Institutes of Health (NIH), grant IM-1P from the American Cancer Society, and grant 81-173 from the American Heart Association.
labile to extremes of heat and to low pH (S. Swain, J. Watson, R. Booth, and R. Dutton, unpublished results) and did not have the chromatographic properties reported for several other murine BCGF preparations (5, 6, 13) .
In particular, the (EL4)BCGF reported by Howard and colleagues (6) , when assayed on anti-#-induced B cells was more stable with a molecular weight of -~ 18,000 by gel filtration analysis, whereas (DL)BCGF gave low recoveries and activity in the 50,000-70,000 mol wt fractions (S. Swain, G. Wetzel, and R. Dutton, unpublished results). We therefore undertook a series of experiments to compare the activities of (DL)BCGF and two other BCGF preparations (EL4 and FS6.14.13) using three assay systems. The results of these experiments reveal the existence of two distinct classes of BCGF that can be distinguished by the assays in which they can be measured. We have provisionally designated these two classes as BCGF I and BCGF II. The data suggest that BCGF I and BCGF II are active on B cells in different stages of differentiation and/or that they are specific for two subsets of B cells.
Materials and Methods

Animals
Mice of strains CBA/N, DBA/2J, C57BL/6J, BALB/c, and BALB/cByJ were raised in our own colony from breeding pairs originally obtained from The Jackson Laboratory, Bar Harbor, ME. BALB/cKe breeding pairs were obtained from the Salk Institute, La Jolla, CA. All F1 hybrid mice were bred in our own colony.
Monoctonal Antibodies (MAb)
The cell line making anti-Thy-l.2, F7D5 was a kind gift from Dr. Phil Lake, then at University College, London, England. The line making anti-Thy-l.2, H0.13.4 was a kind gift of Dr. Ann Marshak-Rothstein, Massachusetts Institute of Technology, Cambridge, MA, and the line making anti-Lyt-2.2, AD4.15 was a kind gift of Dr. Michael Bevan, Research Institute of Scripps Clinic, La Jolla, CA. All antibodies were from ascites taken from Pristane-injected mice inoculated with tumor cells.
Tumor Lines
The in vivo-passed BCL tumor was a kind gift of Dr. Sam Strober, Stanford University School of Medicine, Stanford, CA (15) . The tumor was maintained by intravenous injection of 106 cells from the spleen of tumor-bearing mice 6-10 wk after inoculation. BALB/cByJ or BALB/cKe were used interchangeably as tumor-bearing animals. Palpable tumors appeared in these mice 4 wk after injection. Tumor cells were used in proliferation experiments at any time between 1 wk after the appearance of tumors (5 wk post-injection) and the death of the animals (8-10 wk). BCL1 cells were B cells that expressed IgM (16) .
Factor Preparations
Sources of BCGF. (DL)BCGF was obtained as described previously (3, 17) from the supernatants of the C.C3.11.75 line either after stimulation with non-T cells, after no stimulation, or after stimulation with interleukin 2 (IL-2)-containing supernatants (3). The preparations used in these studies were all extensively characterized. They contained no IL-I or IL-2 (17) and many of them did not contain interferon (IFN) (J. Klein, unpublished results). Most preparations did contain (DL) T cell-replacing factor (TRF), but their activity in the proliferation assays was not related to their content of TRF (3).
(EL4)BCGF was prepared from phorbol myristate acetate (PMA)-stimulated EL4 thymoma cells as detailed previously (6, 18) . The BCGF was separated from IL-2 and TRF in these same supernatants by phenyI-Sepharose column chromatography as described elsewhere (18) . The final preparation contained no IL-1, IL-2, TRF, or IFN (18, 19 ; J. Klein, unpublished results).
(FS6)BCGF was an ammonium sulfate-concentrated preparation from concanavalin A (Con A)-stimulated FS6.14.13 hybridoma cells as described elsewhere (20) . This supernatant was previously reported to have BCGF activity (21, 22) . The supernatants used in these experiments contain large amounts of IL-2 but do not contain TRF or IFN.
(B151K12)BCGF was a kind gift of Dr. K. Takatsu, Osaka University, Japan. The preparation used in these experiments was constitutive supernatant from the B 151 K 12 hybridoma prepared as described previously (23) . This supernatant contains TRF activity in a TRF assay (K. Takatsu, unpublished results), in addition to its BCGF activity (3), but not IFN (J. Klein, unpublished results). Bulk EL4 supernatant was the unseparated supernatant of PMA-stimulated cultures and is known to contain IL-2, TRF, and BCGF activities (6, 19) .
BW.Mls supernatants were obtained by Con A stimulation of a hybridoma made by fusing BW5147 and short-term in vitro Mls-specific T cells (CBA/CaJ stimulated with CBA/J) (T. Beardsley and S. Swain, unpublished results). Supernatants made from subclones of the original are found that are respectively enriched for either IL-2 or BCGF (S. Swain, unpublished results). An ammonium sulfate concentrate rich in BCGF activity but with little IL-2 was used in the BCGF assays. No TRF or IFN is found in these supernatants.
Sources oflL2. IL-2jw was highly purified from Con A supernatant of normal spleen cells by chromatography and isoelectric focusing as described previously (24) . IL-2EL, was prepared from the same unseparated EL4 supernatants that were the source of(EL4)BCGF. The IL-2-containing fractions were taken after phenyl-Sepharose chromatography. They contained no BCGF or TRF (18, 19) . I L2Bw.M~s was obtained from supernatants of certain clones of BW.MIs, described above, that produced high amounts of IL-2 and very little BCGF.
Anti-Ig Sources
Anti-Ig was either selected goat anti-mouse ~-chain (whole affinity-purified Ig (6) or F(ab')2 fragments prepared from rabbit antibodies to Ig (7, 21) . Anti-~ or anti-Ig was generally used in concentrations of 2-10 #g in synergy with BCGF.
Mitogens
Lipopolysaccharide (LPS) was obtained from Escherichia coli 055:B5 by the Westphal technique and was purchased from Difco Laboratories, Detroit, MI. Dextran sulfate (DXS) was a sodium salt, 17% sulfur, 500,000 mol wt (Gibco Laboratories, Grand Island, NY).
ASSOyS
Normal B Cells B cells were prepared as described previously (3, 6) by slight modification of the procedure described previously (20, 25) . Mice were injected at days -3 and -1 or at day -2 with 0.06 ml antithymocyte serum (Mirobiological Associates, Walkersville, MD). Spleens of such mice were removed and treated with a cocktail of anti-T cell MAb including two anti-Thy-l.2, anti-Lyt-l.2, and/or anti-Lyt-2.2, and in some cases MK2.2 (20) . T-depleted spleens were passaged through Sephadex G-10. Cells were 4 5 cultured in triplicate at concentrations ranging from 2 × 10 to 1 × 10 per well with Determination of Cell Cycle State. Two-color flow cytofluorometry was used to simultaneously determine DNA content and RNA content of individual cells. A minimum of 10,000 cells were stained with acridine orange as described in detail elsewhere? The fluorescence signals of each cell were optically separated into two wavelength bands: green (510-550 nm) corresponding to DNA content, and red (>630 nm) corresponding to RNA content. This was possible since AO interacts monomerically with DNA, yielding a characteristic fluorescence maximum at 530 rim, but interacts multimerically with singlestranded RNA and shows a fluorescence maximum at 640 nm. This technique of cell cycle analysis has the advantage that resting Go cells can be distinguished from activated G1 phase cells.
Results
(DL)BCGF Does Not Synergize with Anti-I~ for the Proliferation of Normal or BCL1 Tumor B Cells. The proliferation of highly T-depleted B cells to (EL4)BCGF is
dependent, at low cell numbers per culture, on the presence of anti-Ig of either goat origin (6) or F(ab')2 fragments from rabbits (22) . (DL)BCGF was tested in four separate laboratories for its ability to synergize with anti-Ig preparations in this type of assay. The results of two representative experiments are illustrated in Fig. 1 . Fig. 1A shows that although phenyl Sepharose-purified (non-IL-2-containing) (EL4)BCGF gives very good proliferation of normal B cells in the presence of anti-#, the addition of anti-# did not enhance (DL)BCGF-dependent proliferation. Fig. 1 B shows a similar experiment comparing (DL)BCGF with factors present in concentrated supernatants of FS6.14.13. This second experiment was run in the presence of saturating levels of IL-1 from P388D1 (25) as well as anti-Ig, thus ensuring that IL-1 limitation was not contributing to the failure of DL supernatants to support proliferation. The third panel ( Fig. 1 C) shows that the same (DL)BCGF preparation very actively supports the proliferation of the BCL~ tumor line and that the addition of anti-# to this assay does not enhance the proliferation induced by (DL)BCGF.
(EL4) BCGF and (FS6)BCGF Do Not Support Proliferation of BCL1 Cells. (EL4)
and (FS6)BCGF were next tested for their abilities to support the proliferation of the BCL1 tumor. As shown in Fig. 2 , neither of these factors supports BCL~ proliferation, in marked contrast to (DL)BCGF.
(DL)BCGF Causes the Proliferation of Normal B Cells Costimulated With DXS.
In an earlier study (3), we found that (DL)BCGF had a direct effect on normal B cells. The amount of proliferation seen in these normal B cells was small, however, and we suggested that it might be acting on a small subpopulation of already activated normal B cells that might be in a similar stage of development as the BCL1 tumor cells (3) . We have recently found that up to 90% of BCL1 tumor cells isolated from BALB/c mice are cycling cells with a large proportion in G1, whereas normal B cells are >95% resting cells in Go (Table I) Tables II and III show our success in developing a costimulator assay with normal B cells and DXS. DXS stimulates a portion of B cells to go from Go to G~ states (Table I) , but by itself is quite ineffective in stimulating normal B cell proliferation (Table II) . The addition of (DL)BCGF to DXS-costimulated B cells causes a very impressive synergy in B cell proliferation (Table II and Fig. 3 ). As might be predicted, DXS has no effect on the already high proliferation of BCL~ B cells (Table II) . It seems then that DXS has an effect on all or a subset of normal B cells which causes them to become responsive to (DL)BCGF.
(EL4)BCGF Does Not Have Activity in the DXS-B Cell
Costimulator Assay. Next we tested whether (EL4)BCGF, which had activity in the anti-# costimulator assay, would also synergize with DXS in normal B cell proliferation. (EL4)BCGF did not synergize with DXS for the proliferative response of either unstimulated or DXS-activated normal B cells (Fig. 3) . A further comparison of the effects of different sources of growth factors, including the unfractionated PMA-induced supernatant from the EL4 line, Con A-induced FS6.14.13 supernatants, the B151K12 line (23), and our BW.MIs hybridoma line, are shown in Table III experiments. We will designate those BCGF activities that score in the anti-Ig costimulator assays and whose prototype is (EL4)BCGF as tentatively belonging to the BCGF I class, and those which score in the BCLI proliferation assay and costimulate with DXS in normal B cell proliferation, whose prototype is (DL)BCGF, as belonging to the BCGF II class. A summary of the activities of a variety of different factor preparations in these assays is contained in Table IV . In addition to (EL4)BCGF and FS6, BCGF I activity is found in unseparated EL4 supernatants. BCGF II activity is found in supernatants we have tested from the BW.MIs line, B 151 K 12 hybridoma, and bulk EL4 supernatants. Discussion The testing of a variety of sources of BCGF activities in a panel of different B cell proliferation assays has allowed us to describe two distinct classes of BCGF whose prototypes are (EL4)BCGF and (DL)BCGF. We have provisionally named these two classes BCGF I and BCGF II, respectively. BCGF I causes the proliferation of normal B cells that have been costimulated with anti-Ig but does not costimulate proliferation with DXS or stimulate proliferation of the BCL~ tumor line. In a reciprocal fashion, BCGF II has no enhancing effect on the proliferation of normal B cells plus anti-Ig, but is very effective at costimulating in the presence of DXS and at stimulating the proliferation of the BCL1 tumor line. Supernatants of various cell lines and hybridomas have been tested for these activities and many have one or both of them.
Two possible interpretations of the significance of these results for normal B cell responses can be considered. It is possible either that these two growth factors have effects on different stages of the differentiation of one subset of B cells or that they act on two separate lineages of B cells. This issue cannot be resolved from the data available, but it is worthwhile considering what we know about the individual assays and reagents for a background to approaching this question. BCGF preparations were screened in three proliferation assays. Factor preparations were added over a range of 10-0.016% per culture. Peak proliferation is shown and was usually found at the 10 or 2% factor addition. Factor preparations listed below have all been tested in at least three such assays with similar results. * FS6.14.13 was a 50x ammonium sulfate concentrate of a Con A-induced supernatant. * DL supernatant from one batch of DL. Other batches gave similar results. 0 EL4 was purified BCGF separated from EL4 supernatant, as described in Materials and Methods. I B 151 was a 3 x concentrated supernatant from the B 151K 12 line, a kind gift of Dr. K. Takatsu. ' "EL4 unseparated" was unseparated PMA-induced supernatant of the EL4 line. ** BW.MIs was the concentrated supernatant of the Con A-induced BW.MIs line as described in Materials and Methods.
The anti-Ig synergy assay and the BCGF I used in this assay have been extensively characterized (6, 18 ). It appears that anti-Ig by itself causes a size increase in the vast majority of B cells but that only about half of these B cells activated with anti-# go on to proliferate in response to BCGF I (26) . Preliminary data show that anti-Ig and BCGF I must be present very early in the culture, from 0 to 12 h (27) . It has been suggested that anti-Ig is responsible for the transition of resting B cells from Go to G~ and that BCGF I may have an effect early in G~ phase. Completion of the anti-Ig-driven cell cycle requires yet a third stimulus, provided by the monokine IL-1, which appears to act at a later point in G~, driving the cells to enter S phase (27, 28) . The resting B cells that respond to the later parts of this sequence are absent from the spleens of mice with the X-linked CBA/N defect (xid). 4 BCGF I from EL4 has been partially characterized biochemicaily. It has an apparent molecular weight of 18,000 by gel filtration (6), 11,000 and 14,000 by sodium dodecyl sulfate-polyacrylamide electrophoresis (18) , and isoelectric points (pI) of 6.4-6.7 and 7.4-7.6 (18) . A factor that has activity on human B cells in costimulation with anti-t~ and with chromatographic properties similar to those of murine (EL4)BCGF has been recently described by Okada et al. (11) . When the requirements to drive anti-Ig-induced B cells through both proliferation and differentiation to antibody formation are studied, at least two factors, in addition to (EL4)BCGF and IL-1, are required that can be provided by the B 15K 12 hybridoma supernatants and by a pI 4.5 component of EL4 supernatant (19) . Since the B15K12 supernatants contain BCGF II activity (this paper), it is possible that one role of this supernatant is to provide a lateacting growth factor. Consistent with this notion, it has previously been observed that B15K12 supernatants enhance anti-Ig-induced BCGF I-dependent proliferation and increase cell recoveries (19) .
In contrast to the BCGF I assay, the costimulation of DXS and BCGF II described here has not yet been extensively studied. DXS was originally described as a polyclonal B cell activator, thought to be particularly active on immature B cells (29) . When the frequency of B cells able to initiate clonal growth was studied by Wetzel and Kettman (30) in limiting dilution, there was a synergy between LPS and DXS such that together they could induce virtually 100% of all B cells to form clones, whereas LPS alone induced 1.5% and DXS alone induced 0.1-1% (30) . In recent experience, DXS induces 5-40% of cells in bulk cultures of normal splenic B cells to enter G~ phase during the first 48 h of culture (this paper), but only a small amount of division occurs without added factors, a situation similar to that discussed above for anti-# stimulation. The number of GI phase cells found depends largely on the cell density at which the purified B cells are stimulated: at high cell densities (5 × 105/ml), large number of cells enter G1 (up tO 40%), while at lower cell densities (1-2 × 10~), many fewer cells are driven from Go to GI (5-20%) (G. D. Wetzel and S. Swain, unpublished results). This may reflect a requirement for accessary cells for this transition, similar to results found when the effects of LPS stimulation on the B cell cycle are analyzed (31) .
The BCL~ proliferation assay that we first used to identify BCGF II from DL supernatants uses the in vivo BCL~ tumor line originally characterized by Slavin and Strober (1 fi (32, 33) . The results in this report are consistent with the view that BCL~ B cells are reflective of a subset of normal B lymphocytes with a unique response pattern. Whether such a subset is "immature" is unclear since the correlation between surface phenotype of BCL~ and B cells from young mice is purely circumstantial evidence for immaturity and since different lineages of B cells could well become immunocompetent at different stages of B cell ontogeny. The BCL1 cells we harvest from the animal are found to be mostly in G~ phase, with few resting Go cells (Table I) .
The possibility that BCGF I and II act on different cell subsets is easily accommodated by the extensive documentation of B cell subpopulations. In particular, mouse splenic B cells are known to contain two major populations of approximately equal numerical size, defined by expression of B cell surface markers Lyb-3, -5, and -7. B cells either express all three (most often termed Lyb-5 +) or fail to express any of them (Lyb-5-) (for a recent review see reference 34). These two subsets are properly distinguished with the appropriate alloantisera. These antisera are in extremely limited supply, so most of what is known about Lyb-5 + and Lyb-5-B cell subsets has been inferred from experiments using mice with an X-linked defect found in CBA/N mice, which contain only Lyb5-B cells, compared with normal mice which have both Lyb-5 + and Lyb-5-cells. It should be remembered that the Lyb-5-B cells present in the CBA/N mice as well as other cells in their spleens may not be equivalent to those in normal mice (35, 36) . In particular, since they may be more immature, the failure of B cells from xid mice to respond in a situation should not be interpreted as definitively showing that only Lyb-5 ÷ ceils are able to respond. The experimental observation is that most lymphokine-drive proliferation and differentiation in in vitro responses are not seen with B cells from xid mice, except for antigen-specific responses using in vivo-primed cells (reviewed in reference 37). In the latter case, a strict requirement for direct T-B interaction for linked recognition by T cells of Ag and B cell I region products has been seen (38) . Recent experiments of Takatsu (personal communication) suggest that primed B cells from xid mice can indeed respond to TRF. B cells from xid mice do not proliferate in vitro to anti-~ plus BCGF I or to BCGF II in the absence of costimulation (3) . 4 However, our recent experiments (U. Staerz, S. Swain, and R. Dutton, unpublished results) suggest that B cells from mature xid mice can proliferate moderately in response to DXS plus BCGF II and that the addition of DXS, IL-2, and supernatants containing (DL)TRF will produce sheep erythrocyte-specific plaque-forming cells. Thus it is likely that the Lyb-5-cells in xid mice can become responsive to at least some lymphokines after appropriate stimulation (polyclonal mitogens or in vivo priming). It will be necessary to isolate Lyb-5-cells from normal mice to determine if this response profile is also accurate for such cells and to gather further evidence to define whether the two subsets of B cells that respond, respectively, to anti-# plus BCGF I and DXS and BCGF II, correlate with Lyb-5 + and Lyb-5-subsets.
Recent studies (11, 39) have described two classes of BCGF activity in the human system that are made by T cell clones which appear to synergize in the proliferative response of some B cells. One of these, with an apparent molecular weight of "~17,000 synergizes with anti-Ig and appears to correlate with the BCGF I in the murine system. The second factor has a 50,000 mol wt and was active in proliferation of phytohemagglutinin-induced colonies of B cells (11) and of antiidiotype-stimulated BCLL cells (39) . Further biochemical and biological experiments will be needed to determine if the murine BCGF II described herein is equivalent to the second human BCGF, but the circumstantial evidence suggests that this is a serious possibility. If this is so it might be expected that murine BCGF I and II would both contribute to the proliferation of anti-Iginduced B cells and that there is some suggestion that this prediction is born out as discussed above. The facts that the presence of B 15K 12 supernatants, added late (48 h) in the response of anti-#-and BCGF I-stimulated cells, increases the cell recovery at day 5 (19) , and that B 15K 12 contains BCGF II (3 and this report) are consistent with such a model. Taken together these data suggest a model in which BCGF I and II are growth factors of subsets of one lineage of B cells in different states of differentiation. However, they in no way rule out the possibility that a separate lineage of B cells with a different response pattern might also exist and contribute to proliferation in some experimental situations. Summary Several previously described B cell growth factor (BCGF) activities from a number of mouse monoclonal T cell sources were compared in different functional assays. The results indicate that there are two distinct classes of BCGF defined by functional activity and source. BCGF I, whose prototype is (EL4)BCGF, synergized with anti-Ig in the proliferation of normal splenic B cells but had no activity when dextran sulfate (DXS), rather than anti-Ig, was used to costimulate the same source of B cells. BCGF I also failed to directly stimulate BCL1 tumor B cells. In contrast, BCGF II, whose prototype is (DL)BCGF, showed a reciprocal pattern of activity. BCGF II failed to synergize with anti-Igcostimulated normal B cells to give good proliferative responses. Sources of BCGF II also directly stimulated (no anti-Ig or DXS added) B cells of the BCLI tumor-carrying mice. These results suggest that the two BCGF may have activity on two subsets of B cells that respond differentially to induction with the two polyclonal B cell activators, anti-Ig and DXS. The possibilities that these different patterns of response occur in separate lineages of B cells and/or in B cells in different states of differentiation is discussed.
